Adrenal IncidentalomasNCT07198152
Artificial Intelligence Used in Screening Adrenal Nodules
An observational study of Adrenal Incidentalomas and Thoracic CT-scan, run by Peking University First Hospital at 1 site in China.
Trial summary
By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Adrenal Incidentalomas, Thoracic CT-scan
- What is being tested?
- None intervention
- How many people
- 600 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2025to 30 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of individuals aged over 18 years, with no gender restrictions, who underwent chest low-dose CT scans as part of routine physical examinations. Notably, those with a history of malignant tumors are excluded, and only individuals with qualified imaging data (free from poor quality, artifacts, or other issues that hinder analysis) are included.
Who may be able to join
- The age of the population is over 18 years old, regardless of gender;
- Images from chest low-dose CT plain scan during routine physical examination;
Who cannot join
- Patients with a history of malignant tumors;
- Imaging images with poor quality, artifacts, etc., which make analysis impossible.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Peking University First Hospital
Beijing
Peking University First Hospital, +86 66119025
About this study
Official title: The Application of Artificial Intelligence in Screening Adrenal Nodules in Low-dose Chest CT
By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent intellectual property rights that is specifically designed for screening adrenal nodules in chest low-dose CT scans.
- Conditions
- Adrenal Incidentalomas, Thoracic CT-scan
- Being tested
- None intervention
- Keywords
- automatic segment; automatic classification
- Medical subject headings
- Adrenal incidentaloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
None interventionOther
this study is retrospective based on the CT images, which dose include any intervention.
| Study group | Role | What they receive |
|---|---|---|
| Nodular adrenal glands | Adrenal region segmentation and adrenal nodule identification in chest CT via artificial intelligence Receives: Other: None intervention | |
| Normal adrenal glands | Adrenal region delineation and adrenal gland identification in chest CT using artificial intelligence Receives: Other: None intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Diagnostic Accuracy
Measured: From enrollment to the end of collection in one and a half years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2025
- Study start1 Sep 2025
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adrenal IncidentalomasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07198152
- Sponsor's protocol ID
- 2022yan068-002
- Status last verified
- Sep 2024
- First submitted
- 25 Aug 2025
- Last updated
- 30 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Application of Artificial Intelligence in Screening Adrenal Nodules in Low-dose Chest CT
- ClinicalTrials.gov ID
- NCT07198152
- Acronym / sponsor ID
- 2022yan068-002
- Conditions
- Adrenal Incidentalomas, Thoracic CT-scan
- Keywords
- automatic segment; automatic classification
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 30 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent intellectual property rights that is specifically designed for screening adrenal nodules in chest low-dose CT scans.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nodular adrenal glands | – | Other: None interventionAdrenal region segmentation and adrenal nodule identification in chest CT via artificial intelligence |
| Normal adrenal glands | – | Other: None interventionAdrenal region delineation and adrenal gland identification in chest CT using artificial intelligence |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of individuals aged over 18 years, with no gender restrictions, who underwent chest low-dose CT scans as part of routine physical examinations. Notably, those with a history of malignant tumors are excluded, and only individuals with qualified imaging data (free from poor quality, artifacts, or other issues that hinder analysis) are included.
Key inclusion criteria (2 listed)
- The age of the population is over 18 years old, regardless of gender;
- Images from chest low-dose CT plain scan during routine physical examination;
Key exclusion criteria (2 listed)
- Patients with a history of malignant tumors;
- Imaging images with poor quality, artifacts, etc., which make analysis impossible.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| None interventionthis study is retrospective based on the CT images, which dose include any intervention. | Other | Nodular adrenal glands, Normal adrenal glands |
Primary outcome
Overall Diagnostic Accuracy
Time frame: From enrollment to the end of collection in one and a half years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2025.
- MR-11-23-010450Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Adrenal Incidentalomas
RecruitingObservational study
Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors
Pheochromocytoma, Cardiovascular Complication
Recruiting
Ultradian Steroid Rhythms in Adrenal Incidentalomas
Mild Autonomous Cortisol Secretion Adenoma, Non Secreting Adenoma
Recruiting
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Active, not recruitingObservational study
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas
Adrenal Incidentaloma
RecruitingObservational study
Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations
Adrenal Incidentaloma, Hypercortisolism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adrenal Incidentalomas and Thoracic CT-scan, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shiwei Chen (+86 159 1494 4390, 15914944390@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Diagnostic Accuracy (time frame: From enrollment to the end of collection in one and a half years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2025; AzTrials last refreshed its copy on 29 Oct 2026.